AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cefadroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 526 | 50370-12-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 1 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 93 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 78.62 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 95 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.701 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.417 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.532 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.368 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 79.360 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 55.620 | % | High | 1 |
| herg | hERG pIC50 | 4.496 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.698 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.963 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 59.830 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK | 42 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK,TGFBR1,TTK | 19 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.597 | Moderate | 0.70 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.593 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 3.597 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 81.290 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.089 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 62.450 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.007 | % | Moderate | 0.70 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.730 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 87.140 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 58.440 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 899.498 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 17, 1978 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nasal oedema | 923.52 | 30.16 | 181 | 5497 | 6403 | 90616366 |
| Respiratory tract infection | 502.25 | 30.16 | 174 | 5504 | 58904 | 90563865 |
| Oedema | 394.85 | 30.16 | 209 | 5469 | 200086 | 90422683 |
| Asthma | 352.41 | 30.16 | 207 | 5471 | 241953 | 90380816 |
| Drug hypersensitivity | 343.70 | 30.16 | 260 | 5418 | 463349 | 90159420 |
| Cross sensitivity reaction | 342.46 | 30.16 | 69 | 5609 | 2788 | 90619981 |
| Chest pain | 285.51 | 30.16 | 201 | 5477 | 319444 | 90303325 |
| Wheezing | 250.94 | 30.16 | 166 | 5512 | 237914 | 90384855 |
| Cough | 231.58 | 30.16 | 188 | 5490 | 368774 | 90253995 |
| Type IV hypersensitivity reaction | 226.88 | 30.16 | 52 | 5626 | 3874 | 90618895 |
| Pneumonia | 189.43 | 30.16 | 215 | 5463 | 637844 | 89984925 |
| Malaise | 176.42 | 30.16 | 199 | 5479 | 585787 | 90036982 |
| Pain | 171.08 | 30.16 | 256 | 5422 | 996085 | 89626684 |
| Vomiting | 150.11 | 30.16 | 213 | 5465 | 788080 | 89834689 |
| Dyspnoea | 117.21 | 30.16 | 202 | 5476 | 880753 | 89742016 |
| Rash maculo-papular | 83.78 | 30.16 | 44 | 5634 | 40889 | 90581880 |
| Metastatic malignant melanoma | 65.05 | 30.16 | 16 | 5662 | 1608 | 90621161 |
| Urticaria thermal | 64.59 | 30.16 | 13 | 5665 | 520 | 90622249 |
| Administration site erythema | 52.28 | 30.16 | 12 | 5666 | 897 | 90621872 |
| Skin plaque | 36.53 | 30.16 | 16 | 5662 | 9959 | 90612810 |
| Pigmentation disorder | 33.56 | 30.16 | 13 | 5665 | 5936 | 90616833 |
| Iodine allergy | 31.83 | 30.16 | 8 | 5670 | 878 | 90621891 |
| Vitamin B12 deficiency | 30.67 | 30.16 | 13 | 5665 | 7473 | 90615296 |
| Scratch | 30.32 | 30.16 | 14 | 5664 | 9852 | 90612917 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cross sensitivity reaction | 172.23 | 27.38 | 30 | 888 | 1645 | 42618772 |
| Pneumonia haemophilus | 38.90 | 27.38 | 8 | 910 | 1056 | 42619361 |
| Clostridium difficile colitis | 27.73 | 27.38 | 12 | 906 | 21240 | 42599177 |
| Asthma | 27.64 | 27.38 | 17 | 901 | 62297 | 42558120 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nasal oedema | 938.59 | 24.59 | 181 | 5948 | 6658 | 110576512 |
| Respiratory tract infection | 486.36 | 24.59 | 173 | 5956 | 71444 | 110511726 |
| Cross sensitivity reaction | 473.44 | 24.59 | 99 | 6030 | 5468 | 110577702 |
| Oedema | 424.14 | 24.59 | 214 | 5915 | 209762 | 110373408 |
| Asthma | 411.03 | 24.59 | 222 | 5907 | 250069 | 110333101 |
| Drug hypersensitivity | 348.69 | 24.59 | 248 | 5881 | 453842 | 110129328 |
| Chest pain | 273.33 | 24.59 | 199 | 5930 | 376176 | 110206994 |
| Wheezing | 256.36 | 24.59 | 165 | 5964 | 255065 | 110328105 |
| Type IV hypersensitivity reaction | 231.36 | 24.59 | 56 | 6073 | 5977 | 110577193 |
| Cough | 216.75 | 24.59 | 189 | 5940 | 461452 | 110121718 |
| Pain | 197.48 | 24.59 | 252 | 5877 | 954703 | 109628467 |
| Pneumonia | 180.49 | 24.59 | 231 | 5898 | 876483 | 109706687 |
| Malaise | 177.36 | 24.59 | 201 | 5928 | 671618 | 109911552 |
| Vomiting | 141.98 | 24.59 | 210 | 5919 | 910465 | 109672705 |
| Dyspnoea | 100.51 | 24.59 | 201 | 5928 | 1106671 | 109476499 |
| Rash maculo-papular | 66.91 | 24.59 | 45 | 6084 | 74177 | 110508993 |
| Urticaria thermal | 66.22 | 24.59 | 13 | 6116 | 518 | 110582652 |
| Administration site erythema | 62.45 | 24.59 | 12 | 6117 | 427 | 110582743 |
| Drug reaction with eosinophilia and systemic symptoms | 35.03 | 24.59 | 32 | 6097 | 82063 | 110501107 |
| Pigmentation disorder | 32.51 | 24.59 | 13 | 6116 | 7298 | 110575872 |
| Skin plaque | 31.67 | 24.59 | 15 | 6114 | 12630 | 110570540 |
| Vitamin B12 deficiency | 28.52 | 24.59 | 13 | 6116 | 10042 | 110573128 |
| Scratch | 28.29 | 24.59 | 14 | 6115 | 12965 | 110570205 |
| Erythema | 27.44 | 24.59 | 54 | 6075 | 291393 | 110291777 |
| Off label use | 26.04 | 24.59 | 27 | 6102 | 1500158 | 109083012 |
| Veillonella infection | 25.02 | 24.59 | 4 | 6125 | 47 | 110583123 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DB05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
Related Drugs by ATC class:
J01DB First-generation cephalosporins 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Streptococcal tonsillitis | indication | 41582007 | |
| Klebsiella cystitis | indication | 60867007 | |
| Urinary tract infectious disease | indication | 68566005 | |
| Tonsillitis | indication | 90176007 | DOID:10456 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Prevention of Bacterial Endocarditis | off-label use | ||
| Impaired renal function disorder | contraindication | 197663003 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus | Indication |
| Cats | Genitourinary tract infections caused by Escherichia coli | Indication |
| Cats | Genitourinary tract infections caused by Proteus species | Indication |
| Cats | Genitourinary tract infections caused by Staphylococcus aureus | Indication |
| Cats | Skin and soft tissue infections caused by Pasteurella multocida | Indication |
| Cats | Skin and soft tissue infections caused by Staphylococcus epidermidis | Indication |
| Cats | Skin and soft tissue infections caused by Streptococcus species | Indication |
| Dogs | Skin and soft tissue infections caused by Staphylococcus aureus | Indication |
| Dogs | Genitourinary tract infections caused by Escherichia coli | Indication |
| Dogs | Genitourinary tract infections caused by Proteus species | Indication |
| Dogs | Genitourinary tract infections caused by Staphylococcus aureus | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Cefa-Tabs | HQ Specialty Pharma Corp. | 1 |
| Cefa-Drops | HQ Specialty Pharma Corp. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.77 | acidic |
| pKa2 | 9.72 | acidic |
| pKa3 | 13.53 | acidic |
| pKa4 | 7.63 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Solute carrier family 15 member 1 | Transporter | Ki | 2.14 | WOMBAT-PK | |||||
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018151 | VUID |
| N0000146488 | NUI |
| D00257 | KEGG_DRUG |
| 66592-87-8 | SECONDARY_CAS_RN |
| 1297878 | RXNORM |
| C0007538 | UMLSCUI |
| CHEBI:3479 | CHEBI |
| A1APP | PDB_CHEM_ID |
| CHEMBL1644 | ChEMBL_ID |
| DB01140 | DRUGBANK_ID |
| D002434 | MESH_DESCRIPTOR_UI |
| 47965 | PUBCHEM_CID |
| 4831 | IUPHAR_LIGAND_ID |
| 119922-85-9 | SECONDARY_CAS_RN |
| 280111G160 | UNII |
| d00080 | MMSL |
| 13414000 | SNOMEDCT_US |
| 372651006 | SNOMEDCT_US |
| 4018151 | VANDF |
| 004959 | NDDF |
| 280111G160 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3196 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4059 | TABLET | 1000 mg | ORAL | ANDA | 23 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-135 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| CEFADROXIL | Human Prescription Drug Label | 1 | 16590-043 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 16714-388 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 16714-389 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 16714-390 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-427 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-018 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-146 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| CEFADROXIL | Human Prescription Drug Label | 1 | 42549-504 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-503 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 50090-1915 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 50090-6050 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-428 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-2290 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3742 | CAPSULE | 500 mg | ORAL | ANDA | 13 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5693 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 14 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5694 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 14 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-589 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 57237-096 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 57237-097 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | Human Prescription Drug Label | 1 | 57237-098 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
| Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63187-883 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
| CEFADROXIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63304-972 | POWDER, FOR SUSPENSION | 125 mg | ORAL | ANDA | 21 sections |
| CEFADROXIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63304-973 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
| CEFADROXIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63304-974 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |